Matthew B. Klein, Chief Development Officer at PTC THERAPEUTICS, INC. (PTCT), sold 3,944 shares at $46.58 ($185K) on 2021-04-20, disclosed to the SEC on 2021-04-21.
Open-market sale of $185k PTCT by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.17 | 859 | $41K | 22.3% |
| 2 | $46.58 | 1,444 | $67K | 36.3% |
| 3 | $46.58 | 1,444 | $67K | 36.3% |
| 4 | $47.92 | 197 | $9K | 5.1% |
| Total | $46.99 avg | 3,944 | $185K | 100% |
| Filing → |
| PTCT | SELL | 2026-05-15 | $917K | — | Filing → |
| PTCT | SELL | 2026-04-23 | $202K | — | Filing → |
| PTCT | SELL | 2026-03-13 | $171K | — | Filing → |